Table 3.

Prediction of response, remission, and depression-symptom change in all patients during acute phase cognitive therapy (N=523).

Model: Outcome	Predictor	Beta	SE	OR
1: Response	PSQI Global: Acute-phase intercept	−0.760***	0.124	0.47
	PSQI Global: Acute-phase slope	−0.740***	0.138	0.48
2: Response	Sleep problems: Acute-phase intercept	−0.612***	0.112	0.54
	Sleep problems: Acute-phase slope	−0.572***	0.130	0.56
3. Acute-phase remission	PSQI Global: Acute-phase intercept	−1.127***	0.254	0.32
	PSQI Global: Acute-phase slope	−1.307***	0.259	0.27
4. Acute-phase remission	Sleep problems: Acute-phase intercept	−0.841***	0.243	0.43
	Sleep problems: Acute-phase slope	−1.142***	0.254	0.32
5. Depression-symptoms at week 12	PSQI Global: Acute-phase intercept	0.305***	0.044
	PSQI Global: Acute-phase slope	0.455***	0.042
6. Depression-symptoms at week 12	Sleep problems: Acute-phase intercept	0.239***	0.044
	Sleep problems: Acute-phase slope	0.402***	0.046

Note. N = 523. PSQI = Pittsburgh Sleep Quality Index. Sleep-problems scale derived from depression inventories. Depression severity scale does not include sleep items. Models 1-4 are logistic, and models 5-6 are linear, regression. All predictors and the symptoms outcome are standardized (M = 0, SD = 1). All models control depression severity at intake to the acute phase. OR = odds ratio.

^***p < .001, two-tailed. Note: “Response” marks the beginning of clinically significant improvement in depression symptoms, defined as absence of DSM-IV MDD and an HRSD-17 score of ≤ 12. “Remission” is consistent evidence of asymptomatic status, defined as the last seven consecutive acute-phase HRSD scores <7.